NCT04036227View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Healthy
Interventions
DRUG

GS-248

GS-248 oral solution

DRUG

Placebo

Placebo oral solution with the same composition to match active drug

Trial Locations (1)

SE-75237

CTC Clinical Trial Consultants AB, Uppsala

Sponsors

Lead Sponsor

Gesynta Pharma AB
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Gesynta Pharma AB

INDUSTRY